Pseudouridimycin (TFA)

Pseudouridimycin (PUM) TFA is an antibiotic that selectively inhibits bacterial RNA polymerase (RNAP), with an IC50 of about 0.1 μM and MICs of 4-6 μg/mL. Pseudouridimycin TFA is a C-nucleoside analogue that's effective against both Gram-negative and Gram-positive bacteria. Pseudouridimycin TFA inhibits bacterial growth in vitro and shows activity in a mouse model of purulent streptococcal peritonitis[1][2].

Product Specifications

CAS Number

[2760807-99-4]

Product Name Alternative

PUM (TFA)

UNSPSC

12352005

Target

Antibiotic; Bacterial; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-immunoregulation

Field of Research

Infection

Smiles

O=C1NC(C([C@H]2[C@@H]([C@@H]([C@@H](CNC([C@H](CCC(N)=O)N(C(CNC(N)=N)=O)O)=O)O2)O)O)=CN1)=O.OC(C(F)(F)F)=O

Molecular Formula

C19H27F3N8O11

Molecular Weight

600.46

References & Citations

[1]Rosenqvist P, et al. Characterization of C-nucleoside Antimicrobials from Streptomyces albus DSM 40763: Strepturidin is Pseudouridimycin. Sci Rep. 2019 Jun 20;9 (1) :8935.|[2]Kunthavai Pavundurai Chandra, et al. Pseudouridimycin-A Potent Nucleoside Inhibitor of the RNA. ACS Omega. 2023 Feb 13;8 (8) :7989-8000.|[3]Maffioli SI, et al. Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase. Cell. 2017 Jun 15;169 (7) :1240-1248.e23.